DLL4 and VEGFR2 expression and the associated survival rate in GC patients, and viability of GC cell lines following treatment with anti-human DLL4 or ABL001 antibody. (A) DLL4 and VEGFR2 expression was analyzed in the malignant tissues of GC patients from the cBioPortal database. (B) Kaplan-Meier survival plots demonstrating poor prognostic value of DLL4 and VEGFR2 up-regulation, which correlates with a worse overall survival of GC patients. (C) Twelve GC cell lines were treated with different concentrations of anti-hDLL4 and ABL001 for 24 h. Cell viability was then analyzed using WST assay and the assays were performed in triplicate.
